Tsao CW, Aday AW, Almarzooq ZI et al (2023) Heart disease and stroke statistics—2023 update: a report from the american heart association. Circulation 147(8):e93–e621. https://doi.org/10.1161/CIR.0000000000001123
Njoroge JN, Teerlink JR (2021) Pathophysiology and therapeutic approaches to acute decompensated heart failure. Circ Res 128(10):1468–1486. https://doi.org/10.1161/CIRCRESAHA.121.318186
Article CAS PubMed PubMed Central Google Scholar
Brusca SB, Barnett C, Barnhart BJ et al (2019) Role of critical care medicine training in the cardiovascular intensive care unit: survey responses from dual certified critical care cardiologists. J Am Heart Assoc 8(6):e011721. https://doi.org/10.1161/JAHA.118.011721
Article PubMed PubMed Central Google Scholar
Baek SD, Jeung S, Kang JY, Jeon KH (2020) Dialysis-specific factors and incident atrial fibrillation in hemodialysis patients. Ren Fail 42(1):785–791. https://doi.org/10.1080/0886022X.2020.1801467
Article CAS PubMed PubMed Central Google Scholar
Galea R, Cardillo MT, Caroli A et al (2014) Inflammation and C-reactive protein in atrial fibrillation: cause or effect? Tex Heart Inst J 41(5):461–468. https://doi.org/10.14503/THIJ-13-3466
Article PubMed PubMed Central Google Scholar
Avramovski P, Avramovska M, Sotiroski K, Sikole A (2019) Acute-phase proteins as promoters of abdominal aortic calcification in chronic dialysis patients. Saudi J Kidney Dis Transpl 30(2):376–386. https://doi.org/10.4103/1319-2442.256845
O’Neal WT, Efird JT, Qureshi WT et al (2015) Coronary artery calcium progression and atrial fibrillation: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging. https://doi.org/10.1161/CIRCIMAGING.115.003786
Article PubMed PubMed Central Google Scholar
Yang F, Chou D, Schweitzer P, Hanon S (2010) Warfarin in haemodialysis patients with atrial fibrillation: what benefit? EP Europace 12(12):1666–1672. https://doi.org/10.1093/europace/euq387
Nigwekar SU, Thadhani R (2018) Long-term anticoagulation for patients receiving dialysis tilting the benefit-to-risk ratio? Circulation 138(15):1530–1533. https://doi.org/10.1161/CIRCULATIONAHA.118.037091
Almutairi AR, Zhou L, Gellad WF et al (2017) Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther 39(7):1456-1478.e36. https://doi.org/10.1016/j.clinthera.2017.05.358
Article CAS PubMed Google Scholar
Manckoundia P, Nuemi G, Hacquin A et al (2021) Direct oral anticoagulants versus Vitamin K antagonists in patients aged 80 years and older. Int J Environ Res Public Health. https://doi.org/10.3390/ijerph18094443
Article PubMed PubMed Central Google Scholar
de Vriese AS, Caluwé R, van der Meersch H, de Boeck K, de Bacquer D (2021) Safety and efficacy of Vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: A multicenter randomized controlled trial. J Am Soc Nephrol 32(6):1474–1483. https://doi.org/10.1681/ASN.2020111566
Article PubMed PubMed Central Google Scholar
Chen C, Cao Y, Zheng Y et al (2021) Effect of rivaroxaban or apixaban in atrial fibrillation patients with stage 4–5 chronic kidney disease or on dialysis. Cardiovasc Drugs Ther 35(2):273–281. https://doi.org/10.1007/s10557-021-07144-8
Article CAS PubMed Google Scholar
Chen HY, Ou SH, Huang CW et al (2021) Efficacy and safety of direct oral anticoagulants vs warfarin in patients with chronic kidney disease and dialysis patients: a systematic review and meta-analysis. Clin Drug Invest 41(4):341–351. https://doi.org/10.1007/s40261-021-01016-7
Su X, Yan B, Wang L, Lv J, Cheng H, Chen Y (2021) Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis. Am J Kidney Dis 78(5):678-689.e1. https://doi.org/10.1053/j.ajkd.2021.02.328
Article CAS PubMed Google Scholar
Ha J, Gallagher MP, Jun M (2021) The comparative effectiveness and safety of rivaroxaban and warfarin initiation in adults with atrial fibrillation (AF) by egfr category. J Am Soc Nephrol 32:728
Feldberg J, Patel P, Farrell A et al (2019) A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrol Dial Transplant 34(2):265–277. https://doi.org/10.1093/ndt/gfy031
Article CAS PubMed Google Scholar
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71
Article PubMed PubMed Central Google Scholar
Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898
Reinecke H, Engelbertz C, Bauersachs R et al (2023) A randomized controlled trial comparing apixaban with the Vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: The AXADIA-AFNET 8 Study. Circulation 147(4):296–309. https://doi.org/10.1161/CIRCULATIONAHA.122.062779
Article CAS PubMed Google Scholar
Pokorney SD, Chertow GM, Al-Khalidi HR et al (2022) Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation 146(23):1735–1745. https://doi.org/10.1161/CIRCULATIONAHA.121.054990
Schulman S, Kearon C, The Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis. 2005;3(4):692–694. doi:https://doi.org/10.1111/j.1538-7836.2005.01204.x
Wizemann V, Tong L, Satayathum S et al (2010) Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77(12):1098–1106. https://doi.org/10.1038/ki.2009.477
Article CAS PubMed Google Scholar
Aursulesei V, Costache II (2019) Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol 42(8):774–782. https://doi.org/10.1002/clc.23196
Article PubMed PubMed Central Google Scholar
Van Der Meersch H, De Bacquer D, De Vriese AS (2017) Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Am Heart J 184:37–46. https://doi.org/10.1016/j.ahj.2016.09.016
Article CAS PubMed Google Scholar
Randhawa MS, Vishwanath R, Rai MP et al (2020) Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis. JAMA Netw Open 3(4):e202175. https://doi.org/10.1001/jamanetworkopen.2020.2175
Article PubMed PubMed Central Google Scholar
Di Lullo L, Mariani MV, Ronco C et al (2022) Atrial fibrillation and anticoagulant treatment in end-stage renal disease patients: where do we stand? CardioRenal Med 12(4):131–140. https://doi.org/10.1159/000525387
Article CAS PubMed Google Scholar
Di Lullo L, Tripepi G, Ronco C et al (2018) Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data. J Nephrol 31(5):751–756. https://doi.org/10.1007/s40620-018-0501-7
Article CAS PubMed Google Scholar
Jame S, Barnes G (2020) Stroke and thromboembolism prevention in atrial fibrillation. Heart 106(1):10–17. https://doi.org/10.1136/heartjnl-2019-314898
Article CAS PubMed Google Scholar
Hohnloser SH, Hijazi Z, Thomas L et al (2012) Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33(22):2821–2830. https://doi.org/10.1093/eurheartj/ehs274
Comments (0)